GLP-1 RA antiobesity medications: a new panacea?

Author(s):

Richard Payerchin

Key Takeaways

GLP-1 RA antiobesity medications improve body mass index and overall health but are not a cure-all.
These drugs are driving research into the gut-brain axis and its influence on health.
Robert Kushner, MD, offers expert insights based on his extensive experience in obesity and nutrition.
Kushner's work at Northwestern University highlights the importance of these advancements in obesity treatment.

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

Patients are seeing improvements in body mass index and overall health when they take the new GLP-1 RA antiobesity medications. These drugs are not a cure-all, but they are effective and are shifting medicine to study the gut-brain axis and how it affects human health. Here’s an explanation by Robert Kushner, MD, who has made a career as a researcher and author about overweight, obesity and nutrition. He’s also a doctor who has treated patients for years through Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine.

Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.

Subscribe Now!